Abstract
Two recent studies that involve perturbing tumour blood supply provide new hope for anti-cancer therapies. The first uses elegant molecular engineering to achieve tumour-specific blood clots and the second reports the identification of a natural inhibitor, endostatin, which is produced from tumour extracellular matrix.
Original language | English (US) |
---|---|
Pages (from-to) | R282-R285 |
Journal | Current Biology |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - May 1 1997 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Agricultural and Biological Sciences